ATTORNEY DOCKET NO. 19191.0002 SERIAL NO. 09/091,578

IN THE SPECIFICATION

Please replace the paragraph bridging pages 32 and 33 with the following replacement paragraph.

Diagnostica) and Spectrozyme PL (American Diagnostica) and were performed as previously described (18-20). Assays were performed in the presence of the co-factor DESAFIB (American Diagnostica). DESAFIB, a preparation of soluble fibrin monomers, was produced by digesting highly purified human fibrinogen with the protease batroxobin. Batroxobin cleaved the Arg 16 - Gly 17 bond in the Aα-chain of fibrinogen and consequently released fibrinopeptide A. The resulting des-AA-fibrinogen or fibrin I monomers are soluble in the presence of the peptide Gly-Pro - Arg – Pro (SEQ ID NO: 5). The concentration of lys-plasminogen was varied from 0.0125 - 0.2 μM.

In the Sequence Listing, please delete pages 1-2 and substitute therefor pages 1-2 of the Sequence Listing included herewith.

REMARKS

The specification is amended herein on page 33, line 1 to identify "Gly-Pro-Arg-Pro" as SEQ ID NO: 5. With this amendment, this sequence is now referred to with the proper sequence identifier and no new matter is believed to be added by this amendment.

In response to the Notice to Comply With Requirements for Patent Applications

Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures, the sequence on
page 33, line 1, i.e. SEQ ID NO: 5, is now included in the attached substitute Sequence Listing.

Enclosed herewith is a diskette containing the Sequence Listing in this application in computer
readable form (CRF) and a paper copy of the Sequence Listing in compliance with 37 C.F.R. §